1. Home
  2. UVE vs REPL Comparison

UVE vs REPL Comparison

Compare UVE & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UVE
  • REPL
  • Stock Information
  • Founded
  • UVE 1990
  • REPL 2015
  • Country
  • UVE United States
  • REPL United States
  • Employees
  • UVE N/A
  • REPL N/A
  • Industry
  • UVE Property-Casualty Insurers
  • REPL Biotechnology: Pharmaceutical Preparations
  • Sector
  • UVE Finance
  • REPL Health Care
  • Exchange
  • UVE Nasdaq
  • REPL Nasdaq
  • Market Cap
  • UVE 666.1M
  • REPL 547.0M
  • IPO Year
  • UVE 1992
  • REPL 2018
  • Fundamental
  • Price
  • UVE $24.63
  • REPL $5.82
  • Analyst Decision
  • UVE
  • REPL Hold
  • Analyst Count
  • UVE 0
  • REPL 9
  • Target Price
  • UVE N/A
  • REPL $7.00
  • AVG Volume (30 Days)
  • UVE 132.1K
  • REPL 2.1M
  • Earning Date
  • UVE 10-23-2025
  • REPL 11-11-2025
  • Dividend Yield
  • UVE 3.03%
  • REPL N/A
  • EPS Growth
  • UVE N/A
  • REPL N/A
  • EPS
  • UVE 2.28
  • REPL N/A
  • Revenue
  • UVE $1,567,371,000.00
  • REPL N/A
  • Revenue This Year
  • UVE $1.87
  • REPL N/A
  • Revenue Next Year
  • UVE N/A
  • REPL $408.25
  • P/E Ratio
  • UVE $11.13
  • REPL N/A
  • Revenue Growth
  • UVE 5.64
  • REPL N/A
  • 52 Week Low
  • UVE $16.50
  • REPL $2.68
  • 52 Week High
  • UVE $28.49
  • REPL $17.00
  • Technical
  • Relative Strength Index (RSI)
  • UVE 50.16
  • REPL 48.24
  • Support Level
  • UVE $24.13
  • REPL $5.60
  • Resistance Level
  • UVE $24.95
  • REPL $6.15
  • Average True Range (ATR)
  • UVE 0.61
  • REPL 0.33
  • MACD
  • UVE 0.04
  • REPL 0.08
  • Stochastic Oscillator
  • UVE 34.21
  • REPL 41.02

About UVE UNIVERSAL INSURANCE HOLDINGS INC

Universal Insurance Holdings Inc is a private personal residential homeowner insurance company. The company develops, markets, and underwrites insurance products for consumers predominantly in the personal residential homeowners' lines of business and performs substantially all other insurance-related services for its primary insurance entities, including risk management, claims management, and distribution. The company generates revenue from the collection of premiums, earned net interest and dividend income from the investment portfolio, the collection of reinsurance recoverable and financing fees. The company's primary insurance subsidiaries, (UPCIC) and (APPCIC) provide insurance for personal residential: homeowners, renters/tenants, condo unit owners, and other related coverages.

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.

Share on Social Networks: